Lamas-Francis David, Rodríguez-Fernández Carmen Antía, de Esteban-Maciñeira Elia, Silva-Rodríguez Paula, Pardo María, Bande-Rodríguez Manuel, Blanco-Teijeiro María José
Department of Ophthalmology, University Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain.
Department of Ophthalmology, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
Cancers (Basel). 2024 Jul 10;16(14):2510. doi: 10.3390/cancers16142510.
The prognosis of uveal melanoma is significantly influenced by the risk of metastasis, which varies according to clinical and genetic features. Driver mutations can predict the likelihood of disease progression and survival, although the data in the literature are inconsistent. This meta-analysis aimed to evaluate the prognostic significance of driver mutations, including , , , and , in the advancement of uveal melanoma. A comprehensive search of databases yielded relevant studies, and data from 13 studies (848 eyes) were synthesized to assess the impact of these mutations on metastasis-free survival. The mutation and negative immunohistochemistry were associated with a higher risk of metastasis (logHR = 1.44, 95% CI 1.05-1.83). , , and mutations did not show a significant increase in risk. In summary, has proven to reliably predict the likelihood of disease progression in uveal melanoma, while further studies are needed to establish the significance of other driver mutations.
葡萄膜黑色素瘤的预后受转移风险的显著影响，转移风险因临床和基因特征而异。驱动突变可以预测疾病进展和生存的可能性，尽管文献中的数据并不一致。这项荟萃分析旨在评估驱动突变（包括 、 、 和 ）在葡萄膜黑色素瘤进展中的预后意义。对数据库进行全面检索后获得了相关研究，并综合了13项研究（848只眼）的数据，以评估这些突变对无转移生存期的影响。 突变和免疫组化阴性与更高的转移风险相关（对数风险比=1.44，95%置信区间1.05-1.83）。 、 和 突变未显示风险显著增加。总之， 已被证明能够可靠地预测葡萄膜黑色素瘤疾病进展的可能性，而确定其他驱动突变的意义还需要进一步研究。
